within Pharmacolibrary.Drugs.ATC.L;

model L01DC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1.0,
    Cl             = 0.028,
    adminDuration  = 600,
    adminMass      = 0.015,
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Bleomycin is an antineoplastic antibiotic used mainly for the treatment of various cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, ovarian cancer, and certain head and neck cancers. It is usually administered as part of multi-agent chemotherapy regimens. Bleomycin is approved for clinical use, although its application is limited by its potential to cause pulmonary toxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients receiving intravenous bleomycin. Most PK studies include both male and female adults with normal renal function.</p><h4>References</h4><ol><li><p>Mack, JM, et al., &amp; Richter, GT (2022). Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations. <i>Pediatric blood &amp; cancer</i> 69(8) e29733–None. DOI:<a href=&quot;https://doi.org/10.1002/pbc.29733&quot;>10.1002/pbc.29733</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35484878/&quot;>https://pubmed.ncbi.nlm.nih.gov/35484878</a></p></li><li><p>Groselj, A, et al., &amp; Cemazar, M (2016). Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy. <i>Cancer chemotherapy and pharmacology</i> 77(5) 939–947. DOI:<a href=&quot;https://doi.org/10.1007/s00280-016-3004-z&quot;>10.1007/s00280-016-3004-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26992379/&quot;>https://pubmed.ncbi.nlm.nih.gov/26992379</a></p></li><li><p>Alberts, DS, et al., &amp; Salmon, SE (1978). Bleomycin pharmacokinetics in man. I. Intravenous administration. <i>Cancer chemotherapy and pharmacology</i> 1(3) 177–181. DOI:<a href=&quot;https://doi.org/10.1007/BF00253118&quot;>10.1007/BF00253118</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/86392/&quot;>https://pubmed.ncbi.nlm.nih.gov/86392</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01DC01;
